Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Life SciencesNSE:SAILIFE -0.96%19 EV-to-EBIT is 59.79 as of Aug. 21, 2026, which is 27% above its 10-year median of 46.91. GuruFocus rates NSE:SAILIFE with a GF Score™ of 19/100. The stock has 4 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, Sai Life Sciences ranks worse than 89.52% on this metric.
The historical rank and industry rank for Sai Life Sciences's EV-to-EBIT or its related term are showing as below:
NSE:SAILIFE'
s EV-to-EBIT Range Over the Past 10 Years
Min: 34.71 Med: 46.91 Max: 60.39
Current: 59.81
During the past 5 years, the highest EV-to-EBIT of Sai Life Sciences was 60.39. The lowest was 34.71. And the median was 46.91.
NSE:SAILIFE's EV-to-EBIT is ranked worse than 89.52% of 105
companies
in the Medical Diagnostics & Research industry
Industry Median: 24.2
vs NSE:SAILIFE: 59.81
Sai Life Sciences (NSE:SAILIFE) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sai Life Sciences's Enterprise Value for the quarter that ended in Jun. 2026 was ₹262,025 Mil.
Sai Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹5,179 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Life Sciences EV-to-EBIT Related Terms
Sai Life Sciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sai Life Sciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SAILIFE vs TMO, DHR, IDXX: EV-to-EBIT Comparison
For the Diagnostics & Research subindustry, Sai Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Life Sciences EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sai Life Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sai Life Sciences's EV-to-EBIT falls into.
Sai Life Sciences's current Enterprise Value is ₹309,692 Mil.
Sai Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹5,179 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Life Sciences (NSE:SAILIFE) has a EV-to-EBIT of 59.79 as of Aug. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sai Life Sciences and its competitors. This is 27% above median its historical median of 46.91. Over the past decade, Sai Life Sciences' EV-to-EBIT has ranged from 34.71 to 60.39. According to the industry distribution chart, Sai Life Sciences ranks #94 out of 105 companies in the Medical Diagnostics & Research industry, placing it in the top 89.5%.
Is Sai Life Sciences' EV-to-EBIT too high?
Sai Life Sciences' current EV-to-EBIT of 59.79 is 27% above median its 10-year median of 46.91. Over the past 10 years, this metric has ranged from a low of 34.71 to a high of 60.39. The Medical Diagnostics & Research industry median EV-to-EBIT is 24.20. Sai Life Sciences' value of 59.79 is 147.1% above this industry median. Based on the distribution chart, Sai Life Sciences ranks #94 out of 105 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Sai Life Sciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sai Life Sciences ranks #94 out of 105 companies for EV-to-EBIT. This places Sai Life Sciences in the lower half of its industry. The industry median EV-to-EBIT is 24.20. Sai Life Sciences' value of 59.79 is 147.1% above this benchmark. Historically, Sai Life Sciences' own EV-to-EBIT has ranged from 34.71 to 60.39 over the past decade. While the company's 10-year median is 46.91 vs. the industry median of 24.20, Sai Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 24.20, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Life Sciences's current EV-to-EBIT of 59.79 is 147.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sai Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 24.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Life Sciences's current EV-to-EBIT is 59.79, which is 27% above median its own 10-year median of 46.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current EV-to-EBIT of 59.79. The current EV-to-EBIT is 59.79, which is 27% above median its 10-year median of 46.91 and 147.1% above the Medical Diagnostics & Research industry median of 24.20. Sai Life Sciences' overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current EV-to-EBIT is 59.79 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
19GF Score
Get the complete analysis for NSE:SAILIFE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAILIFE has been successfully added to your 
